GET DAILY SIGNALSViatris (VTRS) Delivers Mixed Q3 Results with Raised Full-Year Outlook
Key Takeaways
- Viatris reported third-quarter 2026 total revenues of $3.75 billion, essentially flat versus the prior year and slightly below consensus estimates near $3.8 billion.
- Adjusted earnings per share (EPS, a profit measure that strips out one-time items) came in at $0.71, topping the analyst consensus of $0.64.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $1.20 billion, ahead of expectations and up 4% on a reported basis.
- The company raised the midpoints of its full-year 2026 guidance across revenue, adjusted EBITDA, and adjusted EPS.
- U.S. GAAP (Generally Accepted Accounting Principles) net loss widened to $325 million, driven primarily by a higher income tax provision rather than weaker operations.
- Supply constraints tied to the Nashik, India facility reduced quarterly revenues by roughly $100 million, with a similar impact expected in the fourth quarter.
- For additional detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated Viatris pages.
- Discover actionable market ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
Viatris, a global healthcare company spanning brands, generics, and complex generics, has spent recent years repositioning its portfolio toward higher-margin, more durable products. This third-quarter 2026 report offered investors a progress check on that strategy while also surfacing a notable operational challenge: an FDA inspection issue at its Nashik, India oral solid dose facility. Because the company's results hinge on steady global product availability, the supply disruption became a central theme of the quarter. At the same time, strength in North American complex generics and Greater China brands, alongside an agreement to acquire Pacira BioSciences, underscored management's pivot toward growth. The earnings update mattered as a signal of whether margin expansion could offset lingering supply and competitive pressures. I also checked this using Tickeron’s AI Screener to see how VTRS compares to others in the industry.
Reported Results
Total revenues were $3.75 billion, essentially flat on a reported and operational basis compared with the third quarter of 2025 and slightly below the consensus estimate of about $3.8 billion. Adjusted EPS of $0.71 rose 6% from $0.67 a year earlier and beat the $0.64 consensus, while adjusted EBITDA of $1.20 billion exceeded expectations and improved 4% on a reported basis.
Regionally, Greater China net sales climbed 14% to $702.6 million, and North America grew about 7%, led by estradiol patch products and new injectable launches. Developed Markets declined 2% to $2,215.9 million, Emerging Markets fell 7% to $529.1 million, and the JANZ (Japan, Australia, and New Zealand) segment declined roughly 6%. Adjusted gross margin expanded to 58.0% from 56.0%, reflecting the shift toward higher-margin businesses.
The U.S. GAAP net loss widened to $325 million from $128 million a year earlier, which management attributed mainly to an increased income tax provision on losses in jurisdictions where minimal benefit could be realized. Management also raised full-year 2026 guidance to revenue of $14.70–$14.90 billion, adjusted EBITDA of $4.45–$4.55 billion, and adjusted EPS of $2.56–$2.63.
Market Reaction and Investor Sentiment
VTRS shares were roughly flat immediately after the report, trading near $19.20 to $19.40, as investors weighed the adjusted EPS and EBITDA beats against a modest revenue miss and the widening GAAP net loss. The stock has nonetheless gained more than 50% year to date, reflecting improving sentiment around the company's margin-focused strategy. Reaction to the print appeared measured: stronger-than-expected profitability and a raised full-year outlook provided support, while the top-line shortfall and the Nashik supply disruption tempered enthusiasm. The announced Pacira BioSciences acquisition added another layer of interpretation, with analysts assessing how the deal's patent-protected, non-opioid pain products could accelerate the shift toward higher-margin revenue.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors are likely to focus on several catalysts. First, the remediation timeline at the Nashik facility remains important. Management expects to resume production in the first quarter of 2027 and projects a further roughly $100 million revenue impact in the fourth quarter of 2026, so progress on resolving the FDA's concerns will be closely watched. From what I see, this remains a key variable for the top line.
Second, the Pacira BioSciences acquisition is expected to close by the end of November 2026. Management has said the deal should be immediately accretive to 2027 financial metrics and anticipates more than $50 million in annual cost synergies by the end of 2028, positioning Viatris to become a leader in non-opioid pain management.
Third, the pipeline offers upcoming milestones. A U.S. Food and Drug Administration (FDA) decision on fast-acting meloxicam is targeted for a PDUFA goal date of December 27, 2026, with a potential launch in early 2027. Phase III readouts for selatogrel and cenerimod are expected in the first half of 2027. Finally, investors will monitor whether Greater China growth moderates as hospital procurement policies take hold and whether North American complex generics momentum can be sustained amid competition. I’m watching this closely as the company executes on its repositioning.
Incorporating AI Tools in My Research
When reviewing earnings like these from VTRS, I often turn to Tickeron’s AI Screener for a structured way to compare performance across peers and spot emerging patterns. It helps filter technical signals and fundamentals efficiently, giving a clearer picture of how the stock fits into broader market moves without replacing my own judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VTRS in +2.95% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where VTRS advanced for three days, in 221 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on VTRS as a result. In 56 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for VTRS just turned positive on October 16, 2026. Looking at past instances where VTRS's MACD turned positive, the stock continued to rise in 33 of 48 cases over the following month. The odds of a continued upward trend are 69%.
The Aroon Indicator entered an Uptrend today. In 192 of 282 cases where VTRS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The 10-day RSI Indicator for VTRS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 20 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 25 of 56 cases where VTRS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 45%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
VTRS broke above its upper Bollinger Band on October 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. VTRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.528) is normal, around the industry mean (7.659). P/E Ratio (-51.270) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (3.322) is also within normal values, averaging (2.202). Dividend Yield (0.025) settles around the average of (0.062) among similar stocks. P/S Ratio (1.347) is also within normal values, averaging (181.047).
The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement